opsumit
(macitentan)Actelion Pharmaceuticals US, Inc.
Usage: OPSUMIT is indicated for treating pulmonary arterial hypertension (PAH, WHO Group I) to reduce disease progression and hospitalization risks. Its effectiveness was demonstrated in a long-term study involving patients with various forms of PAH, primarily those with WHO Functional Class II–III symptoms.